ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Neuroprotective Nanoplatform Integrating Antioxidant MXene Nanozymes and Ferroptosis Inhibitors for Targeted Therapy of Cerebral Ischemia-Reperfusion Injury.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Rocket-Inspired Sequentially Targeted Nanotherapeutics for Mitochondrial Regulation and Inflammatory Reprogramming in Ischemic Stroke.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Neuroprotective Nanoplatform Integrating Antioxidant MXene Nanozymes and Ferroptosis Inhibitors for Targeted Therapy of Cerebral Ischemia-Reperfusion Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Bioinformatics Identification and Experimental Validation of Ferroptosis- and Immune Infiltration-Associated Biomarkers in Ischemic Stroke.Current issues in molecular biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Even after successful revascularization in acute ischemic stroke, some patients still develop secondary neuronal damage and functional impairment, known as cerebral ischemia-reperfusion injury (CIRI). The complex pathophysiological cascade within CIRI limits the efficacy of current single-target therapies in clinical practice. To address this, this study innovatively constructs a multifunctional brain-targeted nanoplatform (RFP) designed to synergistically intervene in the multiple pathological pathways of CIRI. This platform co-delivers Pt-based MXene nanozymes (Pt-Ti
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.